Listeriolysin O Secreted by Listeria monocytogenes into the Host Cell Cytosol Is Degraded by the N-End Rule Pathway

Bacterial strains, mammalian cell lines, and reagents.Bacterial strains used in this study are described in Table 1. All strains were derivatives of the streptomycin-resistant L. monocytogenes strain 10403S of serotype 1/2a (11). To construct LLO_WT and LLO_K25X mutant strains, the NodI/PstI fragment containing the LLO-encoding hly gene, including its promoter and the full-length 5′ and 3′ untranslated regions, was subcloned from pPL1 into the integration vector pPL2 (38). Changes to residue K25 were made by site-directed mutagenesis by using standard methods (6). The codon for the (wild-type) Lys residue, at position 1 of the secreted (signal sequence-lacking) LLO, was converted into codons for the following alternative residues: Arg (AGA), Gly (GGT), Val (GTT), Leu (TTA), Phe (TTT), Ala (GCA), and Thr (ACA). For each mutation, the most abundant L. monocytogenes codon, according to the codon usage table from the Kazusa Research Institute (http://www.kazusa.or.jp/codon/), was used. The constructs (verified by DNA sequencing) were introduced into Escherichia coli SM10 and conjugated into the L. monocytogenes Δhly strain DP-L2161 and the Δhly ΔactA strain DP-L4813 (Table 1). The resulting L. monocytogenes strains, containing single-copy integrated plasmids, were verified by PCR using the primer pairs PL102/PL95 and PL93/PL95 (38) and were maintained on selective antibiotic-brain heart infusion (BHI) plates. L. monocytogenes DP-L4813 was produced via allelic exchange by deleting codons encoding residues 7 to 633 of ActA in strain DP-L2161 by using the plasmid pDP-3076 (58). For mammalian cell infection experiments, L. monocytogenes strains were grown without agitation in slanted 15-ml conical tubes overnight at 30°C in BHI broth and washed twice in phosphate-buffered saline (PBS) before infection.

The mouse J774 macrophage cell line was grown at 37°C and 5% CO₂ in Dulbecco modified Eagle medium (DMEM) with a high glucose content (GIBCO/Invitrogen, Carlsbad, CA) and with 7.5% fetal bovine serum (FBS; GemCell, Woodland, CA) and 2 mM glutamine. Mouse L2 fibroblasts were grown as described previously (59). NIH 3T3 cells were grown in DMEM with a high glucose content and 7% FBS (HyClone, Logan, UT). All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. The proteasome inhibitors N-acetyl-L-leucyl-L-leucyl-L-norleucine (LLnL) and MG132 were purchased from Calbiochem (San Diego, CA).

Plasmids encoding Ub-LLO fusions.The pcDNA3-^fDHFR-Ub^R48-X-LLO^1-417-Flag₂ plasmid constructs encoded the previously described (39, 60) ^fDHFR-Ub^R48 moiety (Flag-tagged mouse dihydrofolate reductase [^fDHFR] followed by a mutant Ub moiety containing residue R48 [Ub^R48]) fused to the mature (signal sequence-lacking) LLO protein that also lacked its C-terminal (membrane-interacting) domain 4. In the plasmid designation, X denotes a junctional amino residue of the LLO moiety that becomes N terminal after cotranslational cleavage at the Ub-X junction. In these constructs, X was either Lys, a destabilizing N-terminal residue of the secreted wild-type LLO, or Gly, a stabilizing residue in the N-end rule. The plasmids were constructed using PCR by amplifying the sequence encoding residues 25 to 417 of LLO (LLO^25-417) from genomic DNA of L. monocytogenes and using the primers that made the resulting fragment to encode the Flag epitope as well. The following primers were used: JZ004 (forward primer for the sequence encoding LLO with residue K25 [LLO_K25]), 5′ ATT TCA CCC GGG AAG GAT GCA TCT GCA TTC AAT AAA GAA AAT TCA ATT TCA TCC 3′; JZ006 (forward primer for the sequence encoding LLO with the K25G mutation [LLO_K25G]), 5′ ATT TCA CCC GGG GGC GAT GCA TCT GCA TTC AAT AAA GAA AAT TCA ATT TCA TCC 3′; and JZ008 (reverse primer encoding Flag-tagged LLO_G417), 5′ ATT TCT AGA GCC GCT GCC GCT CTT GTC ATC GTC GTC CTT GTA GTC TCC ATC TGT ATA AGC TTT TGA AGT TGT TTC AAT ATA TTC TGA 3′ (restriction sites are italicized; the codons for the N-terminal residue of LLO and the Flag sequence are underlined). The PCR-produced DNA fragments were verified by sequencing and then digested with SmaI and XbaI and ligated into the SmaI/XbaI-cut plasmid pcDNA3-^fDHFR-Ub^R48-M-cMos (56), replacing the open reading frame encoding Met-Flag-tagged c-Mos. A second Flag-encoding sequence at the 3′ end of the resulting LLO construct was then added at the XbaI site. The plasmid pcDNA3-^fDHFR-Ub^R48-M-cMos^f was derived from pcDNA3-^fDHFR-Ub^R48-M-cMos (56) by introducing a Flag sequence after the XbaI site through PCR.

Assays with transcription-translation reticulocyte lysate.The TNT quick-coupled transcription-translation system (Promega, Madison, WI) was a rabbit reticulocyte lysate premixed with additional components necessary for carrying out transcription and translation in the lysate, including a mixture of amino acids other than Met. [³⁵S]methionine (>1,000 Ci/mmol; Amersham Pharmacia Biotech, Piscataway, NJ) was added to label newly synthesized proteins in reaction mixtures. Reactions were set up according to the manufacturer's instructions and were carried out at 30°C for 1 h, followed by the addition of 1 volume of 2× sample buffer (100 mM Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate [SDS], 20% glycerol, 0.72 M β-mercaptoethanol, 0.1% bromophenol blue), heating at 95°C for 5 min, 10% SDS-polyacrylamide gel electrophoresis (PAGE), and autoradiography. Dipeptides were added to the final concentration of 1 mM. Stock solutions of dipeptides were 0.2 M in PBS containing 0.15 mM bestatin (Sigma).

Pulse-chase and Western analysis with LLO-transfected NIH 3T3 cells.Mouse NIH 3T3 cells grown to ∼60% confluence were transfected with pcDNA3-Ub^R48-X-LLO^25-415-Flag₂ or with the control plasmid pcDNA3 or pcDNA3-^fDHFR-Ub^R48-R-nsP4 (56). For pulse-chase analysis, the medium was replaced with serum-free and methionine/cysteine-free DMEM after 16 h and cells were labeled for 10 min with ³⁵S protein-labeling mixture (PerkinElmer, Wellesley, MA) and then chased in DMEM with 10% FBS for 1 or 2 h. Cells were lysed in a mixture of 1% Triton X-100, 10% glycerol, 0.15 M NaCl, 5 mM Na-EDTA, and 20 mM Na-HEPES (pH 7.5) also containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail (Roche, Pleasanton, CA). The resulting extracts were clarified by centrifugation at 16,000 × g for 15 min, and samples of the supernatants (containing equal amounts of ³⁵S) were processed for immunoprecipitation with anti-Flag beads (Sigma). Immunoprecipitated proteins were fractionated using 10% SDS-PAGE, followed by autoradiography and quantitation with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). For Western blot analysis, cells were transfected for 24 h and then incubated with or without the proteasome inhibitor MG132 (50 μM) for 4 h. Next, cells were washed three times with PBS and then lysed in NP-40 lysis buffer (25 mM Tris [pH 7.5], 1 mM EDTA, 0.1 mM EGTA, 5 mM MgCl₂, 1% NP-40, 10% glycerol, 150 mM NaCl, 0.5 M PMSF, and 1× protease inhibitor cocktail [Roche, Mannheim, Germany]). The extracts were mixed with 2× sample buffer, boiled for 8 min, clarified by a 5-min spin at 16,000 × g, resolved on an 8% SDS-PAGE gel, transferred onto nitrocellulose, and then probed with polyclonal anti-LLO antibody.

N-terminal sequencing of secreted LLO proteins.L. monocytogenes strains secreting either LLO_K25R, LLO_K25V, or LLO_K25G were grown to mid-logarithmic phase in Luria-Bertani (LB)-G1P medium (LB medium containing 25 mM glucose-1-phosphate, 5% activated charcoal, and 50 mM MOPS [morpholinepropanesulfonic acid], pH 7.4), and culture supernatants were precipitated with 10% trichloroacetic acid, washed with acetone, solubilized in SDS-sample buffer, and fractionated using 4 to 12% gradient bis-Tris SDS-PAGE gels (NuPage; Invitrogen). Proteins were transferred onto polyvinylidene difluoride membranes by electroblotting in CAPS buffer {10% methanol-10 mM CAPS [3-(cyclohexylamino)-1-propanesulfonic acid] adjusted to pH 11 with NaOH} using a semidry gel blotter (Bio-Rad, Hercules, CA). Membranes were then stained with Coomassie blue, and the band corresponding to LLO was excised and processed for N-terminal sequencing (first three residues) at the Molecular Structure Facility (University of California, Davis).

Intracellular growth of L. monocytogenes in J774 macrophages and NIH 3T3 cells.Growth curves of L. monocytogenes were determined as previously described (46). Cells were infected at an effective multiplicity of infection of 0.1 (J774 macrophages) or 0.01 (NIH 3T3 cells). Gentamicin at 50 μg/ml was added at 1 h (J774 macrophages) or 1.5 h (NIH 3T3 cells) postinfection (p.i.) for the duration of the experiment. The proteasome inhibitor LLnL (20 μM) was added, when indicated, at 3 h p.i.

Pulse-chase analysis of LLO produced during intracellular growth of L. monocytogenes.The metabolic labeling of bacterial proteins with [³⁵S]methionine during the infection of J774 macrophages was based on the method of Moors et al. (41). J774 cells (2.2 × 10⁶) were seeded onto 60-mm tissue culture dishes in DMEM and were infected the next day with an overnight (stationary-phase) culture of L. monocytogenes for 30 min at a multiplicity of infection of 1. Infected J774 cells were washed three times with PBS, after which DMEM and also, 30 min later, gentamicin (to 10 μg/ml) was added. At 4.5 h p.i., the medium was changed for 30 min to methionine-free (starvation) DMEM containing 2 mM Gln, 10% dialyzed FBS, 225 μg of cycloheximide/ml, and 30 μg of anisomycin/ml. Thereafter, cells were labeled for 1 h in 0.5 ml of the same medium with 0.2 mCi (per plate) of the ³⁵S protein-labeling mixture (PelkinElmer). In some experiments, the proteasome inhibitor LLnL was included at 50 μM in both starvation and labeling media. After 1 h, the labeling medium was replaced with chase medium (DMEM, 7.5% FBS, 2 mM Gln or 20 μg of chloramphenicol/ml, 5 mM Met). At the times indicated below, cell monolayers were washed three times with cold PBS and lysed by the addition of 1 ml of KD lysis buffer (2% Triton X-100, 0.02% saponin, 10 mM EDTA, PBS without Mg²⁺ or Ca²⁺) containing protease inhibitors (1 mM PMSF, 0.3 μM aprotinin, 1 μM leupeptin, and 1 μM pepstatin A). Both bacteria and insoluble mammalian cell contents were removed by a 10-min spin at 16,000 × g. Supernatants were immunoprecipitated with anti-LLO monoclonal antibody B3-19 (43) as described previously (12). The immunoprecipitates were processed (see above) for 7.5% SDS-PAGE, autoradiography, and the quantitation of LLO bands with a Typhoon phosphorimager (Amersham Biosciences, Arlington Heights, IL) and ImageQuant software (Molecular Dynamics). To ensure equivalent levels of infection for all strains, three 12-mm coverslips per dish were included. The coverslips were removed at 4.5 h p.i. and were used to calculate the number of CFU per dish. In experiments that involved the dephosphorylation of immunoprecipitated LLO_K25G, 20 U of calf intestinal phosphatase (New England Biolabs, Beverly, MA) was employed as previously described (12).

Plaque formation in L2 fibroblasts.Plaque formation in mouse L2 fibroblasts was carried out as previously described (59), and plaques were scored by the method of Skoble et al. (58). Briefly, L2 fibroblasts grown to confluence in 6-well tissue culture plates were infected with 0.25 μl (per plate) of PBS-washed overnight cultures of L. monocytogenes. After 1 h, cell monolayers were washed three times with PBS and the medium was replaced with DMEM agar containing 40 μg of gentamicin/ml, the plates were incubated for 3 days, and plaques were visualized using an additional DMEM agar overlay containing 40 μg of gentamicin/ml and neutral red (GIBCO/Invitrogen) after incubation for 8 h. The relative plaque size is reported as a percentage of the wild-type plaque size.

Immunoblotting analysis of LLO.Overnight cultures of L. monocytogenes were diluted 20-fold in LB medium and incubated with shaking for 2.5 h at 37°C to mid-logarithmic phase (optical density at 600 nm [OD₆₀₀] of ∼0.4). Bacteria were washed once with PBS and diluted into prewarmed LB medium to an OD₆₀₀ below 0.01. At various times postinoculation, 1-ml samples were removed for OD₆₀₀ measurements and LLO immunoblotting. The samples were centrifuged at 16,000 × g for 10 min, and the supernatants were removed and precipitated with 10% trichloroacetic acid, washed with acetone, and processed for SDS-PAGE as described above. Fractionated proteins were electroblotted onto nitrocellulose membranes, and LLO was detected using a rabbit polyclonal antibody to LLO (52), horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (IgG) secondary antibody, and the ECL Plus Western blotting kit according to the instructions of the manufacturer (Promega). To quantitate band intensities, parallel samples were resolved by SDS-PAGE and subjected to the same procedure, except that the secondary antibody was Alexa Fluor goat anti-rabbit antibody (Invitrogen), followed by analysis with an Odyssey infrared imager (LI-COR Biosciences, Lincoln, NE).

Mouse infections.Cultures of L. monocytogenes strains encoding the LLO proteins indicated below were prepared in BHI medium as previously described and stored at −80°C (52). On the day of inoculation, the samples were thawed at room temperature and the strains were subcultured into BHI medium and grown to mid-logarithmic phase at 37°C with agitation. Bacterial cultures were washed once with PBS and diluted in PBS to 5 × 10⁶ bacteria per ml. Samples containing 10⁶ bacteria were injected into 7-week-old female BALB/c mice via the tail vein. Animals were sacrificed 24 h after inoculation. The livers and spleens were homogenized in 0.2% saponin, and the level of viable bacteria in each organ was determined by plating samples of homogenates onto LB plates. Competitive indices for wild-type 10403S L. monocytogenes versus Δhly bacteria expressing LLO_K25X (where X is the N-terminal replacement residue) from an integrated plasmid harboring a chloramphenicol resistance gene were determined essentially as described in reference 5. In this assay, the L. monocytogenes hly deletion strain that was complemented with wild-type LLO (L. monocytogenes LLO_WT) had a minor virulence defect compared to 10403S. The ratios of bacteria of LLO_K25X-expressing strains to 10403S bacteria were determined by plating organ homogenates onto LB plates and then patching 100 colonies onto chloramphenicol (20-μg/ml)-containing plates. The 50% lethal dose (LD₅₀) of each L. monocytogenes strain for BALB/c mice was determined by Cerus Pharmaceuticals (Concord, CA) essentially as previously described (46) except that mice were injected with twofold dilutions and monitored for 7 days postinoculation.

LLO is a substrate of the N-end rule pathway.Mammalian reticulocytes (immature red blood cells) and their ATP-supplemented lysates contain an active Ub system including the N-end rule pathway (15, 26, 48). We asked whether LLO with the wild-type N-terminal residue Lys (Lys-LLO; derived from a Ub-Lys-LLO fusion) would be an N-end rule substrate in reticulocyte lysate. Our experiments utilized the Ub fusion technique (65), which makes it possible to engineer any protein to be expressed, in vivo or in vitro, as a Ub fusion whose (largely) cotranslational deubiquitylation yields a protein of interest with a desired N-terminal residue. The N-end rule pathway can be selectively inhibited in the lysate by the addition of dipeptides bearing either type 1 or type 2 destabilizing N-terminal residues. Through their interaction with, respectively, type 1 and type 2 substrate-binding sites of the ubiquitin-protein ligase E3 component N-recognin UBR1 and other N-recognins (see the introduction; also Fig. 1), such dipeptides act as specific competitive inhibitors of the N-end rule pathway (15, 26, 48). Since Lys, the N-terminal residue of wild-type LLO, is a type 1 primary destabilizing residue (Fig. 1), the degradation of Lys-LLO in reticulocyte lysate would be expected to be inhibited by a dipeptide such as, e.g., Arg-Ala, which bears a type 1 destabilizing N-terminal residue, but not by, e.g., Ala-Arg.

A transcription-translation reticulocyte lysate (see Materials and Methods) was used to express Lys-LLO^25-415 (Ub-Lys-LLO^25-415), which differed from wild-type LLO in lacking the C-terminal membrane-binding domain. These assays (Fig. 2A) utilized the previously developed Ub-protein-reference (UPR) technique, which increases the accuracy of such assays by providing a built-in reference protein (39, 60, 65). This method employs a linear fusion in which Ub is located between a protein of interest and a long-lived reference protein moiety, such as the mouse DHFR. The fusion is cotranslationally cleaved by Ub-specific deubiquitylating enzymes after the last residue of Ub, producing equimolar amounts of the protein of interest and the reference protein bearing the C-terminal Ub moiety. The UPR technique can thus compensate for differences in protein yields and sample volumes and other sources of sample-to-sample variation (39, 65).

• Open in new tab
• Download powerpoint

FIG. 2.

LLO is a substrate of the N-end rule pathway. (A) A plasmid encoding the UPR technique-based fusion comprising ^fDHFR-Ub^R48 and Flag-tagged Lys-LLO^25-415 (see Results) was expressed in a transcription-translation rabbit reticulocyte extract in the presence of [³⁵S]methionine for 1 h at 30°C, after which the extract was analyzed by SDS-PAGE and autoradiography. The above-mentioned fusion was cotranslationally processed into ^fDHFR-Ub^R48 (a long-lived reference protein) and Flag-tagged Lys-LLO^25-415 (see Results). Lane 1, results of analysis in the absence of added dipeptides (−); lane 2, same as lane 1 but in the presence of 1 mM Arg-Ala (RA); lane 3, same as lane 1 but in the presence of 1 mM Ala-Arg (AR); lanes 4 to 6, same as lanes 1 to 3 but with Flag-tagged Gly-LLO^25-415; lanes 7 and 8, same as lanes 1 to 3 but with the control N-end rule substrate Arg-nsP4, a Sindbis virus RNA polymerase with a destabilizing N-terminal Arg (15, 56). (B) Stabilization of Flag-tagged Lys-LLO^25-415 in mouse NIH 3T3 cells by the inhibition of host proteasomes. The cells were transiently transfected with the plasmid pcDNA3 or plasmid constructs pcDNA3-Ub^R48-X-LLO^25-415-Flag₂ (where X represents Lys or Gly). After 24 h, cells were either left untreated (−; lanes 1, 3, and 5) or incubated with the proteasome inhibitor MG132 (50 μM) for 4 h (+; lanes 2, 4, and 6) before cells were lysed and the extracts were processed for Western blotting with polyclonal anti-LLO antibody. The asterisk (*) indicates nonspecific bands that served as internal loading controls. (C) Degradation of Flag-tagged Lys-LLO^25-415 and Gly-LLO^25-415 in mouse NIH 3T3 cells. The cells were transiently transfected with pcDNA3-Ub^R48-X-LLO^25-415-Flag₂ plasmids. Cells were pulse-labeled with [³⁵S]methionine for 10 min and chased for 1 and 2 h, after which they were subjected to immunoprecipitation with anti-Flag antibody, SDS-PAGE, and autoradiography. Lane 1, vector alone (control [C]); lanes 2 to 4, cells expressing Flag-tagged Lys-LLO^25-415; lanes 5 to 7, cells expressing Flag-tagged Gly-LLO^25-415. (D) Quantification of the pulse-chase patterns in panel B, with the amount of Flag-tagged Gly-LLO^25-415 at the end of the pulse taken as 100%.

Using the previously described and validated steady-state assay with reticulocyte lysate (15), we determined the levels of ³⁵S-labeled synthesized Lys-LLO^25-415 in the lysate relative to the levels of the DHFR-Ub reference. In the presence of the Arg-Ala dipeptide, which bears a destabilizing N-terminal residue of the same (type 1) class as that of Lys-LLO (Fig. 1), the level of Lys-LLO^25-415 in the lysate was much higher than either in the presence of (compositionally identical) Ala-Arg or in the absence of added dipeptides (Fig. 2A, lanes 1 to 3). As expected, Phe-Ala, which contained a type 2 destabilizing N-terminal residue (Fig. 1), did not increase the levels of Lys-LLO^25-415 (data not shown), in contrast to Arg-Ala. This inhibitor-based evidence that ³⁵S-labeled Lys-LLO^25-415 in the lysate was targeted for degradation by the N-end rule pathway was independently supported by the results of an otherwise identical assay with Gly-LLO^25-415, which differed from Lys-LLO^25-415 solely by its N-terminal residue. (Gly is a stabilizing residue in the N-end rule [Fig. 1].) In contrast to those of Lys-LLO^25-415, the levels of ³⁵S-labeled Gly-LLO^25-415 produced in reticulocyte lysate were not altered by the addition of Arg-Ala, thus confirming, in a different way, that Lys-LLO^25-415 was degraded by the N-end rule pathway in reticulocyte lysate. The likely flexibility of LLO's N-terminal region, as evaluated by analogy with the similar perfringolysin O toxin of Clostridium perfringens (49) and the use of Phyre (http://www.sbg.bio.ic.ac.uk/phyre/) three-dimensional prediction software, presumably contributes to the targeting of Lys-LLO by the N-end rule pathway, given the previously established requirement for a flexible region downstream of a substrate's destabilizing N-terminal residue as one determinant of the substrate's N-degron (see the introduction).

To verify that Lys-LLO^25-415 was degraded by the N-end rule pathway in vivo as well, mouse NIH 3T3 cells were transiently transfected with plasmids that expressed either Lys-LLO^25-415 or Gly-LLO^25-415, the latter bearing a stabilizing N-terminal residue, with both test proteins produced by deubiquitylation of their Ub fusions (see above). We analyzed LLO degradation in NIH 3T3 cells by using both immunoblotting and pulse-chase assays. In the pulse-chase assays, the band of Gly-LLO^25-415 was prominent at the end of the 10-min pulse and remained undiminished throughout a 2-h chase, whereas the band of Lys-LLO^25-415 was barely detectable (at the same level of autoradiographic exposure) even before the chase, i.e., at the end of the 10-min pulse (Fig. 2C, lanes 2 to 4; compare lanes 5 to 7). While longer exposures than that for the sample shown in Fig. 2C allowed the detection of the band of pulse-labeled Lys-LLO^25-415, the quantitation of the band patterns confirmed the much lower level of pulse-labeled Lys-LLO^25-415 than of Gly-LLO^25-415 in NIH 3T3 cells, indicating the rapid degradation of Lys-LLO^25-415 during the 10-min pulse, i.e., even before the chase (Fig. 2D and data not shown). Interestingly, whereas young (pulse-labeled) molecules of Lys-LLO^25-415 were rapidly degraded by the N-end rule pathway in vivo, those (relatively few) molecules of Lys-LLO^25-415 that escaped degradation shortly after their synthesis were degraded at later times (during the chase) apparently at a much lower rate than their newly formed (young) counterparts (Fig. 2D). In other words, the activity of the N-degron of Lys-LLO^25-415 apparently decreased as a function of time posttranslation. This effect, previously observed with other N-end rule substrates (and substrates of other Ub-dependent pathways as well) is likely to stem, at least in part, from conformational changes (conformational maturation) that newly formed proteins undergo soon after their synthesis, including, for oligomeric proteins, the formation of either homo- or hetero-oligomers (9, 60).

Without proteasome inhibitors, Lys-LLO^25-415 was undetectable by immunoblotting, whereas Gly-LLO^25-415 was readily detectable (Fig. 2B, lanes 3 and 5). In striking contrast, the level of Lys-LLO^25-415 was greatly increased in NIH 3T3 cells after 4 h of treatment with MG132, a proteasome inhibitor, whereas the same treatment only marginally increased the level Gly-LLO^25-415 (Fig. 2B, lanes 3 to 6). Taken together, the above-cited in vitro (Fig. 1) and in vivo (Fig. 2) evidence identified Lys-LLO^25-415 as a substrate of the mammalian N-end rule pathway. These data also suggest that LLO may contain at least one other, apparently weaker, degron that is targeted by a non-N-end rule pathway.

L. monocytogenes strains secreting LLOs with different N-terminal residues.To examine whether secreted LLOs bearing either destabilizing or stabilizing N-terminal residues (Fig. 1) would exhibit different functional properties and result in bacteria with different abilities to infect (and grow in) mammalian hosts, we began by constructing L. monocytogenes strains that secreted X-LLOs, in which X was either Gly or Val (stabilizing residues in the N-end rule), Arg (a type 1 destabilizing residue), Leu or Phe (type 2 destabilizing residues), Ala, or Thr. The latter two N-terminal residues, and Ser as well, can be destabilizing under certain conditions (26), but the corresponding N-recognin, i.e., an E3 Ub ligase(s) specific for N-terminal Ala, Thr, and Ser, has not been identified. In addition, N-terminal Ala, Thr, and Ser residues are often acetylated in vivo, a modification that would be expected to preclude their recognition as destabilizing residues.

LLO_K25R, LLO_K25V, and LLO_K25G that were secreted by the corresponding L. monocytogenes strains were isolated to determine their N-terminal residues by Edman sequencing (see Materials and Methods). These tests directly confirmed the presence of Arg, Val, and Gly, respectively, at the N termini of the above-listed (mutant) X-LLO proteins, indicating that the residues that replaced wild-type Lys-25 did not alter the signal sequence cleavage site of LLO.

Previous work has shown that the 5′ untranslated region and the 5′-proximal part of the LLO-encoding hly mRNA are involved in regulating LLO synthesis during growth in vitro and in mammalian cells as well (52, 55). In particular, a single-codon change at residue Ser-44 of LLO that retained Ser as the encoded residue strongly increased LLO production, resulting in host cell toxicity and intracellular growth and virulence defects (24, 52, 53). To determine whether the above-described alterations of the N-terminal residue of secreted LLO affect LLO synthesis, we assayed the relative amounts of mutant LLO_K25X proteins that were produced during the in vitro growth of the corresponding L. monocytogenes strains. These tests included the LLO_S44S L. monocytogenes mutant that produces a wild-type LLO but exhibits increased translation of the LLO mRNA during logarithmic growth (52).

The mutant L. monocytogenes strains grew indistinguishably from wild-type L. monocytogenes in both LB and BHI broth (Fig. 3A and data not shown). The relative levels of secreted LLO_K25X proteins (determined by immunoblotting) were similar for all of the tested strains at the late stationary phase of growth in LB broth (Fig. 3B). In addition, all of the mutant LLO_K25X proteins had activities similar to those of pore-forming proteins, as determined by assaying their abilities to lyse red blood cells (Fig. 3C). Furthermore, the alterations of the N-terminal residues in LLO_K25X proteins did not affect the pH optimum of LLO (Table 2). There were small differences in the amounts of secreted LLO_K25X proteins during exponential in vitro growth, although all of the observed differences were much below the ∼9-fold overproduction of LLO by the LLO_S44S L. monocytogenes mutant (Fig. 3B). Since the secreted LLO is not degraded in the medium during the in vitro growth of L. monocytogenes (52), the various levels of LLO_K25X proteins produced by exponentially growing cells were most likely due to (relatively small) alterations in the rate of LLO synthesis. Thus, the mutational alterations of the N-terminal residue of the secreted LLO resulted in (at most) minor changes in the rate of its production and did not alter the pore-forming activity of LLO (Fig. 3 and Table 2).

• Open in new tab
• Download powerpoint

FIG. 3.

Secretion of LLO bearing different N-terminal residues by L. monocytogenes strains growing outside host cells. (A and B) Growth (A) and LLO secretion (B) in LB medium by L. monocytogenes strains that produced either wild-type (WT) Lys-LLO or its derivatives containing other (indicated) N-terminal residues. The relative amounts of secreted X-LLO proteins (in mid-logarithmic [mid log], late-logarithmic [late log], and stationary [stat] phases of growth) were compared by immunoblotting. Shown are the results of one of five independent experiments. The numbers below the first row in panel B (which include standard deviations) refer to the quantitation of immunoblots from three samples taken during mid-exponential growth and analyzed with an Odyssey infrared imager. (C) Hemolytic activity of LLO present in stationary-phase culture supernatants from the L. monocytogenes strains with the indicated mutations. Error bars indicate standard deviations for three replicates in one experiment that is representative of four independent experiments. sRBCs, sheep red blood cells.

Stabilization of LLO against degradation by the N-end rule pathway has minor effects on the intracellular growth or virulence of L. monocytogenes.We next examined the ability of the above-mentioned L. monocytogenes mutants to grow intracellularly in mammalian cells. The rates of growth of the L. monocytogenes LLO_K25X mutants in mouse J774 macrophage-like cells for the first 8 h were lower than the rate of growth of the wild-type strain by up to twofold (Fig. 4A). By 11 h p.i., the strains expressing LLO_K25G, LLO_K25V, LLO_K25A, and LLO_K25T exhibited a retardation of growth of up to fourfold in J774 cells (Fig. 4A). The strains expressing LLO_K25R, LLO_K25L, and LLO_K25F (in which the wild-type destabilizing Lys residue was changed to another destabilizing residue) continued to exhibit at most twofold-slower growth than wild-type L. monocytogenes (Fig. 4A). However, none of the above-listed LLO mutants had a substantial growth defect in NIH 3T3 fibroblasts (Fig. 4B) or in the (3-day) plaque formation assay, which integrates both the intracellular growth of L. monocytogenes and its ability to infect neighboring cells (Fig. 4C). In contrast, L. monocytogenes LLO_S44S, which expresses strongly increased levels of LLO, exhibited a ∼50-fold reduction in intracellular growth in J774 cells by 8 h p.i. and was unable to form plaques in L2 cell monolayers (52). Finally, we found that the L. monocytogenes LLO_K25X mutants exhibited close to wild-type levels of virulence as measured by the LD₅₀s for BALB/c mice (Table 2), although minor virulence defects (up to a 1.9-fold reduction) in the liver were detected for the L. monocytogenes LLO_K25V strain relative to L. monocytogenes LLO_WT when the strains were directly compared to wild-type L. monocytogenes 10403S in the competitive index assay (see Fig. 7B and Discussion). Taken together, these results indicate that while the metabolic stabilization of secreted X-LLO detectably compromised the intracellular growth, cell-to-cell spread, and virulence of L. monocytogenes, the effects observed were relatively small (Fig. 3 and 4 and Table 2).

• Open in new tab
• Download powerpoint

FIG. 4.

Alterations of LLO's N-terminal residue have at most weak effects on the intracellular growth of L. monocytogenes. (A and B) Growth curves of L. monocytogenes LLO_WT (WT; expressing Lys-LLO) and LLO_K25X mutants (identified by the corresponding mutations) in J774 macrophages (A) and NIH 3T3 fibroblasts (B) (see Materials and Methods). Shown here are the results, including standard deviations, of one of at least three independent experiments with triplicate coverslips for each experiment. The P values for the growth difference between the LLO_WT and LLO_K25X strains of L. monocytogenes were 0.008 and 0.035 at 8 and 11 h p.i., respectively (based on Student's t test for one sample; http://www.statpages.org). (C) Sizes of plaques formed in mouse L2 fibroblasts by L. monocytogenes strains that produced the indicated X-LLO proteins relative to the size of plaques formed by the wild-type strain expressing Lys-LLO, which was set as 100%. Standard deviations were compiled from the results of three independent experiments.

The identity of LLO's N-terminal residue affects LLO degradation in mammalian cytosol.LLO secreted from L. monocytogenes into the host cell cytosol becomes phosphorylated and ubiquitylated before its rapid, proteasome-dependent degradation (53). However, LLO secreted during cell-to-cell spread appears to be proteolytically cleaved but is otherwise longer lived, suggesting the existence of metabolically distinct subpopulations of LLO (53). To confine the analysis to LLO that is degraded in vivo, we introduced the wild-type and LLO_K25X mutant alleles into an L. monocytogenes strain with a deletion of actA. The actA gene encodes a bacterial protein required for actin polymerization and the intercellular dissemination of L. monocytogenes (18, 34, 61). The absence of cell-to-cell spread did not result in a detectable effect on the intracellular growth of L. monocytogenes strains that secreted either LLO_WT or LLO_K25X by up to 8 h p.i. (data not shown).

Using pulse-chase analysis, we found that changing the N terminus of LLO from Lys to Arg, another type 1 primary destabilizing residue (Fig. 1), did not significantly affect the rate of LLO degradation (Fig. 5A). In contrast, the placement of other residues, including stabilizing residues, at the LLO N terminus led to a strong, up to 10-fold, metabolic stabilization of X-LLO (Fig. 5A). Stabilized X-LLO migrated as both a 58-kDa band (a species that comigrates with the full-length LLO minus the signal sequence) and a 60-kDa band. The latter, in the case of wild-type LLO, was previously shown to be its phosphorylated derivative (52). In agreement with this conclusion, phosphatase treatment shifted the 60-kDa species of immunoprecipitated LLO_K25G to the 58-kDa form (Fig. 5B). In addition, larger (>60-kDa) LLO-containing species, which were previously shown to be ubiquitylated derivatives of LLO (53), were also observed (Fig. 5).

• Open in new tab
• Download powerpoint

FIG. 5.

Alterations of LLO's N-terminal residue affect its degradation in the host cell cytosol. (A) Pulse-chase analysis of X-LLO proteins (where X is Lys [wild type], Arg, Leu, Phe, Ala, Thr, Gly, or Val). X-LLOs were immunoprecipitated from extracts of J774 macrophages that were infected with nonspreading (actAΔ) L. monocytogenes strains secreting the indicated X-LLO proteins. P and C in panel A refer to pulse and chase, respectively. Cells were labeled at 5 h p.i. for 1 h with [³⁵S]methionine and, when indicated, chased for 30 min, after which they were subjected to immunoprecipitation with anti-LLO antibody, SDS-PAGE, and quantitation (see Materials and Methods). The band intensities after the chase, relative to those immediately after the pulse, were used to estimate the approximate half-lives (T_1/2) of X-LLO proteins. Shown are the results from one of two independent experiments. WT, wild type. (B) Immunoprecipitated LLO_K25G (Gly-LLO; lane 1) was incubated either with buffer only (lane 2) or with buffer containing calf intestinal phosphatase (CIP; lane 3) for 20 h at 37°C prior to SDS-PAGE (lane 3). (C) X-LLOs with the indicated mutations were labeled with [³⁵S]methionine at 5 h p.i. for 30 min in the presence (+) of LLnL (see Materials and Methods). rel. levels, relative levels.

For reasons unknown, the replacement of a type 1 destabilizing residue such as Lys by a type 2 destabilizing residue such as Phe or Leu at the N terminus of LLO significantly stabilized the resulting X-LLO during the chase (Fig. 5A). However, the initial (postpulse) levels of Phe-LLO and Leu-LLO were lower than those of their counterparts in the case of, for example, Thr-LLO and Gly-LLO (Fig. 5A). These data are in agreement with the observed decrease in LLO production during the in vitro growth of L. monocytogenes, i.e., in the absence of host cells (Fig. 3B). Indeed, when the degradation of secreted X-LLO in the mouse cell cytosol was inhibited, during pulse-labeling, by the proteasome inhibitor LLnL, the relative levels of pulse-labeled X-LLOs closely corresponded to those observed during the exponential growth of L. monocytogenes in the absence of host cells (Fig. 5C and 3B). Taken together, the patterns of X-LLO degradation in reticulocyte extract and in mouse NIH 3T3 cells (Fig. 2), as well as the degradation patterns of secreted X-LLO in the host cytosol (Fig. 5A), were a (qualitatively) self-consistent set, demonstrating directly that wild-type LLO, bearing N-terminal Lys, is a physiological substrate of the N-end rule pathway.

Synergistic impairment of intracellular growth of L. monocytogenes by a combination of overproduction and metabolic stabilization of LLO.Our previous work has shown that a higher rate of LLO production is synergistically cytotoxic with the metabolic stabilization of LLO, the latter achieved by the pharmacological inhibition of the proteasome (24, 52, 53). Specifically, treatment with a proteasome inhibitor has negligible effects on the intracellular growth of wild-type L. monocytogenes, but the same treatment results in high LLO-mediated toxicity when combined with mutations that increase the rate of LLO synthesis and secretion (52, 53). These results suggested that the proteasomal degradation of LLO becomes critical for intracellular growth when LLO is synthesized at higher-than-wild-type levels. To address these issues by stabilizing X-LLO through changes of its N-terminal residue (instead of a much less specific, metabolically pleiotropic inhibition of the proteasome), we constructed a panel of L. monocytogenes strains that combined alterations of the N-terminal residue of secreted LLO with the synonymous codon change at residue S44 that increases the rate of LLO production and secretion into the host cytosol at the level of LLO translation during cytosolic growth (52).

The analysis of the resulting double mutant bacteria revealed strikingly high levels of X-LLO toxicity (up to a 100-fold reduction in growth over 8 h p.i) when the S44S mutation was combined with a stabilizing N-terminal residue (Fig. 6). Through visual monitoring of the infection, it was clear that the observed synergistic growth defect of the K25X-S44S double mutants stemmed, in a large part, from their toxicity to the infected host cell (data not shown). Under the conditions of our assay, this toxicity was manifested as an increase in plasma membrane permeability. The increased permeability reduced the number of CFU through the influx of the bactericidal antibiotic gentamicin from the medium into the host cell, the lysis of the host cell, and the subsequent exposure of the bacteria to gentamicin in the medium. When a change of the N-terminal residue of LLO reduced the production of LLO both in vitro (in the absence of host cells) and during intracellular growth (Fig. 3B and 5C), the degree of synergism between a (partially) stabilizing N-terminal alteration and the S44S mutation was also reduced (K25F and S44S) or lacking altogether (K25L and S44S) (Fig. 6). We conclude that LLO-mediated toxicity depends on the rates of both the production and degradation of LLO.

• Open in new tab
• Download powerpoint

FIG. 6.

Synergistic effects of both overproducing LLO and increasing its in vivo half-life on the intracellular growth of L. monocytogenes in mouse cells. Graphs depict the intracellular growth, in J774 macrophages, of L. monocytogenes strains that overproduced LLO (owing to the LLO_S44S mutation) and, when indicated, also contained mutational alterations of the N-terminal residue of LLO (K25X). See Materials and Methods for technical details. Error bars indicate standard deviations of results for triplicate coverslips from one experiment representative of three independent experiments.

To explore further the effects of LLO degradation by the N-end rule pathway on the virulence of L. monocytogenes, we analyzed the S44S mutant and the K25X-S44S double mutants in the murine model of listeriosis (Fig. 7A and Materials and Methods). Strikingly, the levels of CFU of each L. monocytogenes mutant recovered from the spleens of infected mice strongly correlated with the observed growth defects of the corresponding mutant in the J774 macrophage cell culture model. Specifically, the replacement of the (wild-type) N-terminal Lys residue of LLO by stabilizing residues strongly increased the virulence defect of L. monocytogenes LLO_S44S in BALB/c mice, up to 100-fold after 24 h p.i. (Fig. 1, 6, and 7A). A similar pattern in the livers of infected mice was observed (Fig. 7A). While an effect of metabolically stabilized LLO_K25V on the virulence of the corresponding single-mutant strain appeared to be lacking when measured by the LD₅₀ for BALB/c mice (Table 2), an up to nearly twofold decrease in virulence in the liver could be reproducibly detected using the competitive index assay (Fig. 7B) and is briefly considered below.

• Open in new tab
• Download powerpoint

FIG. 7.

Metabolic stabilization of LLO decreases the virulence of L. monocytogenes in mice. (A) BALB/c mice were inoculated, by tail vein injection, with 10⁶ bacteria of the L. monocytogenes strains with the indicated mutations. All bacteria contained the LLO S44S mutation that results in the overproduction of LLO and, in addition, either the wild-type N-terminal Lys residue of LLO or its replacement residue, as shown. CFU were recovered from the livers and spleens 24 h postinoculation by plating dilutions of organ homogenates onto LB plates. Values shown represent the pooled data from at least three independent experiments, with five mice per strain of L. monocytogenes. Black horizontal bars indicate median values for each data set. (B) Competitive indices of L. monocytogenes 10403S versus the complemented hly deletion strains expressing either wild-type LLO or LLO_K25V. A 1:1 mixture of complemented Δhly L. monocytogenes and wild-type 10403S L. monocytogenes was coinjected into the tail veins of BALB/c mice. The ratio of each strain in the livers and spleens was determined by plating organ homogenates and subsequently screening 100 colonies for the chloramphenicol resistance phenotype of the complemented strain. The P values indicated were obtained with Student's t test for two samples (http://www.statpages.org).